Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3

Conditions

Gastrointestinal Stromal Tumors 3Mastocytosis, Systemic 1Leukemia, Mast-Cell 1

Interventions

Sunitinib 16Imatinib Mesylate 13nilotinib 8ripretinib 4regorafenib 4avapritinib 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3pexidartinib 2pembrolizumab 2Bevacizumab 2trametinib 1tinostamustine 1spartalizumab 1romidepsin 1ponatinib 1pazopanib 1palbociclib 1olaratumab 1guadecitabine 1ferric carboxymaltose 1epacadostat 1dabrafenib 1cediranib 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sorafenib 1STA 9090 1Observation 1Iron-Dextran Complex 1Indocyanine Green 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Stromal Tumors × avapritinib × Clear all
NCT04825574 2024-11-26

Study for Patients Previously Treated in Avapritinib Clinical Trials

Blueprint Medicines Corporation

Phase 4 Completed
2 enrolled 4 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03465722 2022-10-06

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

Blueprint Medicines Corporation

Phase 3 Completed
476 enrolled 14 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02508532 2022-06-21

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Blueprint Medicines Corporation

Phase 1 Completed
250 enrolled 36 charts 1 FDA
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡